Karo Pharma AB (KARO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Karo Pharma AB (KARO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH59487D
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Karo Pharma AB (Karo Pharma), formerly Karo Bio AB, is a health care company that focuses on research and development of pharmaceutical products in the areas of cancer and autoimmune diseases. Its key research area involves nuclear receptors as target proteins for the development of new pharmaceuticals. Karo Pharma discovers drugs to target major diseases including autoimmune diseases such as multiple sclerosis; and multiple types of cancer, viral and bacterial infections. The company's projects are based on ROR gamma receptor and estrogen receptor. Its development pipeline also includes T268A Cold Spray which utilizes glucose oxidase enzyme in combination with glucose to fight against cold virus. Karo Pharma is headquartered in Huddinge, Stockholm, Sweden.

Karo Pharma AB (KARO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Karo Pharma AB, Medical Devices Deals, 2011 to YTD 2017 11

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Karo Pharma AB, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Karo Bio Enters Into Research Agreement With 4D Science 13

Karo Bio Extends Research Agreement With Pfizer For RORgamma Modulators 13

Karo Bio Enters Into Research Agreement With Pfizer For RORgamma Modulators 14

Karo Bio Extends Research Agreement With Zydus Cadila 15

Licensing Agreements 16

Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 16

Karo Bio Enters Into Licensing Agreement With Alkem 17

Equity Offering 18

Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 18

Karo Bio Raises USD29 Million in Rights Offering of Shares 19

Karo Bio Raises USD12 Million in Rights Offering of Shares 21

Karo Bio Raises USD1 Million in Private Placement of Shares 21

Karo Bio Completes Rights Offering of Shares for USD4.9 Million 22

Asset Transactions 23

Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 23

Acquisition 24

Karo Pharma Acquires 100% Stake in Medireduce 24

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 25

Karo Bio Acquires Tanomed for USD2.3 Million 26

Bluefish Pharma Acquires BMM Pharma From BioPhausia 27

Medivir Completes Acquisition Of BioPhausia For USD95 Million 28

Karo Pharma AB-Key Competitors 30

Key Employees 31

Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

May 10, 2017: Karo Pharma: interim report January-March-2017 33

Feb 28, 2017: Karo Pharma: Full Year Report 2016 35

Oct 27, 2016: Karo Pharma: Interim Report January-September 2016 36

Jul 15, 2016: Karo Pharma: Interim Report January-June 2016 37

May 12, 2016: Karo Bio: Interim Report January-March 2016 38

Feb 12, 2016: Year-End Report 2015-Karo Bio 40

Other Significant Developments 43

May 04, 2017: Karo Pharma-Pfizer Collaboration reaches second milestone 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44

List of Figures

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Karo Pharma AB, Medical Devices Deals, 2011 to YTD 2017 11

List of Tables

Karo Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Karo Pharma AB, Deals By Therapy Area, 2011 to YTD 2017 9

Karo Pharma AB, Medical Devices Deals, 2011 to YTD 2017 11

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Karo Bio Enters Into Research Agreement With 4D Science 13

Karo Bio Extends Research Agreement With Pfizer For RORgamma Modulators 13

Karo Bio Enters Into Research Agreement With Pfizer For RORgamma Modulators 14

Karo Bio Extends Research Agreement With Zydus Cadila 15

Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 16

Karo Bio Enters Into Licensing Agreement With Alkem 17

Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 18

Karo Bio Raises USD29 Million in Rights Offering of Shares 19

Karo Bio Raises USD12 Million in Rights Offering of Shares 21

Karo Bio Raises USD1 Million in Private Placement of Shares 21

Karo Bio Completes Rights Offering of Shares for USD4.9 Million 22

Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 23

Karo Pharma Acquires 100% Stake in Medireduce 24

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 25

Karo Bio Acquires Tanomed for USD2.3 Million 26

Bluefish Pharma Acquires BMM Pharma From BioPhausia 27

Medivir Completes Acquisition Of BioPhausia For USD95 Million 28

Karo Pharma AB, Key Competitors 30

Karo Pharma AB, Key Employees 31

Karo Pharma AB, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Karo Pharma AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16140
Site License
USD 500 INR 32280
Corporate User License
USD 750 INR 48420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com